ECSP21028914A - Proteínas de fusión de péptido similar al glucagón 1 (glp1)-factor de diferenciación de crecimiento 15 (gdf15) y usos de estas - Google Patents

Proteínas de fusión de péptido similar al glucagón 1 (glp1)-factor de diferenciación de crecimiento 15 (gdf15) y usos de estas

Info

Publication number
ECSP21028914A
ECSP21028914A ECSENADI202128914A ECDI202128914A ECSP21028914A EC SP21028914 A ECSP21028914 A EC SP21028914A EC SENADI202128914 A ECSENADI202128914 A EC SENADI202128914A EC DI202128914 A ECDI202128914 A EC DI202128914A EC SP21028914 A ECSP21028914 A EC SP21028914A
Authority
EC
Ecuador
Prior art keywords
glp1
gdf15
fusion proteins
glucagon
differentiation factor
Prior art date
Application number
ECSENADI202128914A
Other languages
English (en)
Inventor
Songmao Zheng
Jennifer Furman
Shamina Rangwala
Xiefan Lin-Schmidt
Matthew M Rankin
Chichi Huang
Serena Nelson
Shannon Mullican
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ECSP21028914A publication Critical patent/ECSP21028914A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente descripción se proporcionan proteínas de fusión de GLP1-GDF15 que comprenden un GLP1 o un péptido variante de GLP1, un primer péptido enlazador, una proteína de albúmina sérica, un segundo péptido enlazador, y una proteína GDF15.
ECSENADI202128914A 2018-10-22 2021-04-22 Proteínas de fusión de péptido similar al glucagón 1 (glp1)-factor de diferenciación de crecimiento 15 (gdf15) y usos de estas ECSP21028914A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862748603P 2018-10-22 2018-10-22

Publications (1)

Publication Number Publication Date
ECSP21028914A true ECSP21028914A (es) 2021-05-31

Family

ID=70330680

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202128914A ECSP21028914A (es) 2018-10-22 2021-04-22 Proteínas de fusión de péptido similar al glucagón 1 (glp1)-factor de diferenciación de crecimiento 15 (gdf15) y usos de estas

Country Status (22)

Country Link
US (2) US11713345B2 (es)
EP (1) EP3870211A4 (es)
JP (1) JP7539902B2 (es)
KR (1) KR20210081389A (es)
CN (1) CN113226351A (es)
AU (1) AU2019368816A1 (es)
BR (1) BR112021007376A2 (es)
CA (1) CA3116983A1 (es)
CL (1) CL2021000987A1 (es)
CO (1) CO2021005051A2 (es)
CR (1) CR20210193A (es)
DO (1) DOP2021000075A (es)
EA (1) EA202191105A1 (es)
EC (1) ECSP21028914A (es)
IL (1) IL282297A (es)
JO (1) JOP20210084A1 (es)
MX (1) MX2021004665A (es)
PE (1) PE20211078A1 (es)
PH (1) PH12021550885A1 (es)
SA (1) SA521421825B1 (es)
SG (1) SG11202103990QA (es)
WO (1) WO2020084496A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
WO2020104948A1 (en) * 2018-11-20 2020-05-28 Janssen Pharmaceutica Nv Gdf15 analogs and methods for use in decreasing body weight and/or reducing food intake
EP4085077A4 (en) * 2019-12-31 2024-01-17 Beijing QL Biopharmaceutical Co., Ltd. FUSION PROTEINS FROM GLP-1 AND GDF15 AND CONJUGATES THEREOF
US11981718B2 (en) * 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
WO2022221291A2 (en) * 2021-04-12 2022-10-20 University Of Florida Research Foundation Incorporated Compositions and methods for treating obesity
WO2022245183A1 (en) * 2021-05-21 2022-11-24 Yuhan Corporation Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant
EP4351627A1 (en) * 2021-05-21 2024-04-17 Yuhan Corporation Composition for combination therapy comprising growth differentiation factor-15 variant and glucagon-like peptide-1 receptor agonist
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases
KR20240087545A (ko) * 2022-11-18 2024-06-19 주식회사유한양행 이중 작용 단백질 및 이의 용도
CN116813742A (zh) * 2022-11-22 2023-09-29 杭州博茵生物技术有限公司 人gdf-15抗原表位肽、抗原、抗体、试剂盒及应用
WO2024144431A1 (ru) * 2022-12-29 2024-07-04 Авва Фармасьютикалс Лтд Новый штамм-продуцент escherichia coli, продуцирующий гибридный белок cbd-hs-es-glp1, и способ получения полипептида glp-1
WO2024155160A1 (ko) * 2023-01-20 2024-07-25 한국과학기술원 Gfral을 표적으로 하는 안티센스 올리고머 및 이의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ306180B6 (cs) * 2000-12-07 2016-09-14 Eli Lilly And Company GLP-1 fúzní proteiny
US8071103B2 (en) 2006-07-18 2011-12-06 Centocor, Inc. Pharmaceutical composition comprising a human GLP-1 mimetibody
EP2291399B1 (en) 2008-05-22 2014-06-25 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
US9012719B2 (en) 2009-02-06 2015-04-21 Syngenta Participations Ag Modification of multidomain enzyme for expression in plants
EP2658873B1 (en) 2010-12-27 2019-08-21 Apo-T B.V. A cross linking polypeptide comprising a tetrameric single chain antibody binding mhc-mage complex that induces apoptosis
HUE041499T2 (hu) * 2012-11-21 2019-05-28 Janssen Biotech Inc Bispecifikus EGFR/C-MET-ellenanyagok
JP6272907B2 (ja) * 2013-01-30 2018-01-31 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害の処置における組成物及び使用方法
KR20160021183A (ko) 2013-06-20 2016-02-24 노보 노르디스크 에이/에스 Glp-1 유도체 및 그것의 용도
EP3763734A1 (en) * 2013-07-31 2021-01-13 Amgen Inc. Growth differentiation factor 15 (gdf-15) constructs
GB201403794D0 (en) * 2014-03-04 2014-04-16 Univ Manchester Novel antimicrobial peptides
WO2015198199A1 (en) 2014-06-23 2015-12-30 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof.
US10588980B2 (en) * 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
EP3423094A4 (en) * 2016-02-29 2019-11-06 Eli Lilly and Company GFRAL RECEPTOR THERAPIES
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof

Also Published As

Publication number Publication date
US11713345B2 (en) 2023-08-01
AU2019368816A1 (en) 2021-05-13
EA202191105A1 (ru) 2021-08-03
EP3870211A4 (en) 2022-08-10
CO2021005051A2 (es) 2021-04-30
BR112021007376A2 (pt) 2021-08-10
EP3870211A1 (en) 2021-09-01
IL282297A (en) 2021-05-31
US20230322888A1 (en) 2023-10-12
US20220089669A1 (en) 2022-03-24
CL2021000987A1 (es) 2021-09-10
MX2021004665A (es) 2021-08-24
CR20210193A (es) 2021-06-15
PH12021550885A1 (en) 2022-02-21
SG11202103990QA (en) 2021-05-28
JP7539902B2 (ja) 2024-08-26
KR20210081389A (ko) 2021-07-01
CN113226351A (zh) 2021-08-06
JP2022513363A (ja) 2022-02-07
WO2020084496A1 (en) 2020-04-30
SA521421825B1 (ar) 2024-03-06
PE20211078A1 (es) 2021-06-09
JOP20210084A1 (ar) 2023-01-30
CA3116983A1 (en) 2020-04-30
DOP2021000075A (es) 2021-12-15

Similar Documents

Publication Publication Date Title
ECSP21028914A (es) Proteínas de fusión de péptido similar al glucagón 1 (glp1)-factor de diferenciación de crecimiento 15 (gdf15) y usos de estas
CL2018003148A1 (es) Proteínas de fusión y usos de las mismas.
CO2017002166A2 (es) Proteínas de fusión de interleucina 2 / receptor de interleucina-2 alfa
UY36304A (es) Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes
ECSP064643A (es) Proteinas de fusion de glp-1
PE20210313A1 (es) Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
MX2021000047A (es) Proteina de fusion variante pd1-4-1bbl y procedimientos de uso de la misma.
BR112023024494A2 (pt) Polipeptídeos engenheirados
CO2020012563A2 (es) Proteínas de fusión del factor de diferenciación de crecimiento 15
EA201791238A1 (ru) Способы и композиции, в которых используются варианты полипептидов klotho
WO2016115511A3 (en) Vegf variant polypeptide compositions
RU2017132689A (ru) СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE
MX2021000263A (es) Proteina de fusion variante sirpalfa-4-1bbl y procedimientos de uso de la misma.
PE20190110A1 (es) Proteinas f de prefusion del vrs estabilizadas
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
MX2022006018A (es) Nanoporos artificiales y usos y metodos relacionados con los mismos.
CO2020016008A2 (es) Formulación de proteína de fusión estable
CL2017002687A1 (es) Polipéptidos dirigidos a la fusión de vih
CO2023001488A2 (es) Proteínas de fusión del ligando para flt3 y métodos de uso
WO2020132039A3 (en) Peptide tags for ligand induced degradation of fusion proteins
BR112022005426A2 (pt) Polipeptídeos de fusão dap10/dap12
PE20220500A1 (es) POLIPEPTIDO DE FUSION QUE COMPRENDE LA REGION Fc DE INMUNOGLOBULINA Y GDF15
MX2023001262A (es) Polipéptidos inhibidores del ligando 1 de muerte programada que prolongan la vida media del suero.
EP4059512A4 (en) AQUEOUS PHARMACEUTICAL COMPOSITION CONTAINING SERUM ALBUMIN FUSION PROTEIN AND GROWTH HORMONE
MX2023000373A (es) Proteinas de fusion de proteinas de la espicula de coronavirus estabilizadas.